WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience
QUICK SEARCH:   [advanced]


     
-


HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (137)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Volkow, N. D.
Right arrow Articles by Logan, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Volkow, N. D.
Right arrow Articles by Logan, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*d-METHAMPHETAMINE
*METHYLPHENIDATE
Medline Plus Health Information
*Methamphetamine

 Previous Article  |  Next Article 

The Journal of Neuroscience, December 1, 2001, 21(23):9414-9418

Loss of Dopamine Transporters in Methamphetamine Abusers Recovers with Protracted Abstinence

Nora D. Volkow1, 3, Linda Chang1, 3, Gene-Jack Wang1, Joanna S. Fowler2, Dinko Franceschi1, Mark Sedler3, Samuel J. Gatley1, Eric Miller4, Robert Hitzemann3, Yu-Shin Ding1, and Jean Logan1

1 Medical and 2 Chemistry Departments, Brookhaven National Laboratory, Upton, New York 11973, 3 Department of Psychiatry, State University of New York at Stony Brook, Stony Brook, New York 11794, and 4 Department of Psychiatry, Harbor-University of California, Los Angeles, Torrance, California 90502


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Methamphetamine is a popular drug of abuse that is neurotoxic to dopamine (DA) terminals when administered to laboratory animals. Studies in methamphetamine abusers have also documented significant loss of DA transporters (used as markers of the DA terminal) that are associated with slower motor function and decreased memory. The extent to which the loss of DA transporters predisposes methamphetamine abusers to neurodegenerative disorders such as Parkinsonism is unclear and may depend in part on the degree of recovery. Here we assessed the effects of protracted abstinence on the loss of DA transporters in striatum, in methamphetamine abusers using positron emission tomography and [11C]d-threo-methylphenidate (DA transporter radioligand). Brain DA transporters in five methamphetamine abusers evaluated during short abstinence (<6 months) and then retested during protracted abstinence (12-17 months) showed significant increases with protracted abstinence (caudate, +19%; putamen, +16%). Although performance in some of the tests for which we observed an association with DA transporters showed some improvement, this effect was not significant. The DA transporter increases with abstinence could indicate that methamphetamine-induced DA transporter loss reflects temporary adaptive changes (i.e., downregulation), that the loss reflects DA terminal damage but that terminals can recover, or that remaining viable terminals increase synaptic arborization. Because neuropsychological tests did not improve to the same extent, this suggests that the increase of the DA transporters was not sufficient for complete function recovery. These findings have treatment implications because they suggest that protracted abstinence may reverse some of methamphetamine-induced alterations in brain DA terminals.

Key words: methamphetamine; dopamine transporters; imaging; positron emission tomography; addiction; detoxification; neurotoxicity; dopamine terminal


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The rapidly escalating abuse of methamphetamine (METH) places a sense of urgency on understanding its effects on the human brain and its medical consequences. METH is a particularly problematic drug in that not only is it highly addictive but its administration to laboratory animals results in damage to dopamine (DA) terminals (Seiden and Sabol, 1996). Studies in humans have also documented a significant loss of DA transporters (DAT), which have been used as markers of DA terminals, in the brains of METH abusers (Wilson et al., 1996; McCann et al., 1998; Volkow et al., 2001). Although the DAT loss reported in METH abusers (24-30%) is smaller than that reported in Parkinson's disease (36 and 71%) (Frost et al., 1993; Innis et al., 1993), it is nonetheless associated with reduced motor speed and impaired verbal learning (Volkow et al., 2001). Because significant reductions in DAT occur both with age (6-7% per decade for the 20-80 year age span) (Volkow et al., 1996) and with METH abuse (equivalent to that seen over 40 years of aging), a concern arises as to whether the DAT losses in the METH abusers will place them at risk for Parkinsonism as they age. The extent to which this is likely to occur will depend in part on the reversibility of the changes induced by METH.

Although previous studies proposed that METH-induced DAT losses reflected irreversible terminal degeneration (Ricaurte and McCann, 1992), recent studies in rodents (Friedman et al., 1998; Cass and Manning 1999) and in nonhuman primates (Melega et al., 1997; Harvey et al., 2000) have revealed significant recovery with protracted abstinence. This suggests that either METH-induced damage to the DA terminals recovers or that the DAT losses reflect adaptive changes rather than neurotoxicity. The extent to which a similar recovery may occur in METH abusers has not been investigated. Here we investigate whether the DAT losses in METH abusers recover with protracted abstinence.

For this purpose, we used positron emission tomography (PET) and the DAT radioligand [11C]d-threo-methylphenidate (Volkow et al., 1995) to measure DAT availability in METH abusers. The initial group, which consisted of 12 METH abusers, was tested within 6 months of the last METH administration (Volkow et al., 2001). They were followed and retested at least 9 months later if they remained drug free. Only five METH abusers who were able to stay drug-free were retested at least 9 months later (protracted abstinence). Here we report on the results for the repeated studies in these subjects and on those of five additional METH abusers who were tested only once after having been abstinent for at least 9 months. The DAT measures were compared with those in controls and with those we reported previously in METH abusers tested within 6 months of abstinence (Volkow et al., 2001).


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Subjects. Five METH abusers (three females, two males; 29 ± 3 years of age) were evaluated twice: during early (mean ± SD, 3 ± 1.6 months of abstinence) and then at least 9 months later during protracted abstinence (mean ± SD, 14 ± 2 months). These five METH abusers were the ones from an original sample of 12 METH abusers (Volkow et al., 2001) who were able to remain drug free for at least 9 months since the first PET scan evaluation. In addition, we also evaluated five METH abusers (four females, one male; 35 ± 3 years of age) who were tested only once after having been detoxified for at least 9 months (17 ± 10 months of abstinence). METH abusers fulfilled Diagnostic and Statistical Manual of Mental Disorders IV criteria for METH dependence (average METH use of at least 0.25 gm/d, at least 5 d per week for at least 2 years, at least 2 weeks of METH abstinence). Subjects were excluded if seropositive for human immunodeficiency virus, comorbid neuropsychiatric disorder, medical illness, or current or past history of drug dependence other than METH and nicotine. Details for screening have been published previously (Volkow et al., 2001). METH abusers were enrolled in a California drug-court monitoring rehabilitation program and were evaluated weekly or biweekly with drug screens to ensure lack of drug use during the abstinence period. Controls were 11 healthy non-drug-abusing subjects (seven females, four males; 31 ± 7 years of age) who were screened for lack of a past or present history of drug abuse (except for nicotine or caffeine). Prescan urine tests ensured absence of psychoactive drug use in all subjects. The protocol was approved by the Institutional Review Boards at Brookhaven National Laboratory, State University of New York at Stony Brook, and Harbor-University of California, Los Angeles Medical Center. All subjects gave written informed consent after the experimental procedure was explained and after they had read the consent form.

Scanning. PET scans were performed using a CTI 931 Siemens scanner (spatial resolution, 6 × 6 × 6.5 mm full-width half-maximum). Dynamic scans were started after intravenous injection of 4-8 mCi of [11C]d-threo-methylphenidate (specific activity >0.4 Ci/µmol at time of injection) for a total of 84 min as described previously (Volkow et al., 1995).

Neuropsychological evaluation. In the METH abusers, we assessed performance in neuropsychological tasks, which we showed to be correlated with DAT levels (Volkow et al., 2001). The tests were performed within 2 weeks of the PET studies and included tests for the following: (1) motor function: gross motor function (timed gait, subject walks as fast as possible in a straight line) and fine motor coordination (grooved pegboard, subject inserts pegs in small holes angled in different directions as quickly as possible); and (2) memory function: Rey auditory verbal learning test (subject has to learn and recall lists of unrelated words immediately, after a time delay, and after a distractor).

Image analysis and modeling. Regions in striatum (caudate and putamen) were obtained from three sequential planes and in the cerebellum (CB) from two sequential planes and were drawn on the averaged emission scans (activity between 10 and 84 min). Regions in striatum are selected in multiple planes to increase the reproducibility of the measures (Bendriem et al., 1991). The regions were then projected to the dynamic emission scans to obtain tissue time activity curves. These tissue time activity curves along with the time activity curves for unchanged tracer in plasma were used to calculate the transfer constant of [11C]d-threo-methylphenidate from plasma to brain (K1) and the distribution volumes (DV), which correspond to the equilibrium measurement of the ratio of tissue concentration to plasma concentration, in striatum and CB using a graphical analysis technique for radiotracers with reversible kinetics (Logan et al., 1990). The ratio of DV in striatum to that in cerebellum, which corresponds to (Bmax/Kd) + 1 and is insensitive to changes in cerebral blood flow (Logan et al., 1994), was used as measure of DAT availability.

Statistical analysis. Differences in K1 and Bmax/Kd between the measures obtained in the METH abusers tested during short and protracted abstinence were tested with paired t tests (two tailed). Pearson product correlations were used to assess the relationship between the changes in Bmax/Kd and the lapse in days between the first and the second evaluation and the doses and the years of METH use. Differences in neuropsychological performance between the first and second evaluation were tested with paired t tests. Pearson's product correlations were used to assess the relationship between the changes in DAT and the changes in neuropsychological scores between the first and the second evaluation.

Differences in K1 and Bmax/Kd between the controls and the METH abusers evaluated during protracted abstinence (five METH abusers evaluated only once during protracted abstinence and the data obtained during the second evaluation for the five METH abusers tested twice) and those in the original sample of 12 METH abusers tested during short abstinence (seven females, five males; 30 ± 6 years of age; 64 ± 40 d of abstinence) (Volkow et al., 2001) were tested with factorial ANOVA. Post hoc t tests were done to assess the differences that were significant. Differences between the METH abusers who might have relapsed within 9 months of the first PET evaluation (seven subjects who dropped out from the detoxification program) and those that did not (five subjects) were tested with factorial ANOVA.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

DAT in the five METH abusers tested twice during short and protracted abstinence

In the METH abusers evaluated twice, there were no differences between short and protracted abstinence for K1 in cerebellum (0.45 ± 0.10 vs 0.47 ± 0.11) or in caudate (0.55 ± 0.08 vs 0.55 ± 0.08) or putamen (0.63 ± 0.10 vs 0.63 ±0.09). However, binding of [11C]d-threo-methylphenidate in striatum, but not in cerebellum, was increased between the short and the protracted abstinence (Fig. 1). DAT availability (Bmax/Kd) was significantly increased from short to protracted abstinence in caudate (+19%; p < 0.003) and putamen (+16%; p < 0.05) (Fig. 2). The magnitude of the changes in DAT in putamen were negatively correlated with the reported doses of METH used (r = 0.88; df = 4; p < 0.05), and there was a trend for a negative correlation with the years of METH use (r = 0.83; df = 4; p < 0.08) (Fig. 3A). The later correlations were not significant for the changes in caudate. The correlation between the days between evaluations and the magnitude of the increases in DAT was significant for the averaged changes in caudate and putamen (r = 0.92; df = 4; p < 0.05) (Fig. 3B).



View larger version (47K):
[in this window]
[in a new window]
  		Figure 1.   Brain images of the distribution volume of [11C]d-threo-methylphenidate in a control and a METH abuser. Images shown were obtained at the level of the striatum (images to the left) and the cerebellum (images to the right), and they are from a normal control and a METH abuser evaluated twice, during short and protracted abstinence. Notice the significant increases in binding in striatum in the METH abuser with protracted abstinence.



View larger version (16K):
[in this window]
[in a new window]
  		Figure 2.   Individual measures for DAT availability in the five METH abusers tested twice during short and protracted abstinence. Measures of DAT availability (Bmax/Kd) were significantly increased with protracted abstinence in caudate (p < 0.003) and putamen (p < 0.05). Repeated-measures ANOVA.



View larger version (16K):
[in this window]
[in a new window]
  		Figure 3.   A, Correlation between changes in DAT in putamen between the first and second evaluations and the reported doses (r = 0.88; df = 4; p < 0.05) and years of METH used (r = 0.83; df = 4; p < 0.08). B, Correlation between changes in DAT in striatum between the first and second evaluations and the days elapsed between evaluations (r = 0.92; df = 4; p < 0.05).

Neuropsychological performance in METH abusers tested twice during short and protracted abstinence

Performance in the neuropsychological tests for which we hypothesized a priori an association with DAT measures showed a nonsignificant trend of improvement for timed gait (10.0 ± 1 vs 8.6 ± 2; p < 0.13) and the delayed recall (11.6 ± 3 vs 12.8 ± 2; p < 0.10) but no changes in the pegboard or the immediate or interference recall between the first and second evaluations. Although not significant, there was also a trend for an association between the changes in DAT between the first and second evaluation and the changes in the scores for timed gait (r = 0.78; p < 0.12) and the delayed recall (r = 0.71; p < 0.18).

Comparison between controls and METH abusers tested during short or protracted abstinence

Comparison of DAT availability (Bmax/Kd) between the METH groups tested during short versus those tested during protracted abstinence (these two groups combined the data from METH tested only once and the data from the five METH abusers tested twice) versus controls showed a significant group effect in caudate (F = 7.9; df = 2,30; p < 0.002) and putamen (F = 5.5; df = 2,30; p < 0.01). Post hoc t tests showed that the Bmax/Kd measures in METH abusers tested during short abstinence were significantly lower than those in controls (caudate, 26%; putamen, 21%; p < 0.001), whereas those in the METH abusers tested during protracted abstinence, although slightly lower, did not differ significantly from those in controls (caudate, 5%; putamen, 9%; NS) (Table 1). Differences were also significant between the METH abusers evaluated during short and those evaluated during protracted abstinence in caudate (26% difference; p < 0.01), and there was a trend in putamen (15% difference; p < 0.10) (Table 1). There were no differences between groups on the K1 measures (Table 1).


                              
View this table:
[in this window]
[in a new window]
  		Table 1.   Measures of K1 and DAT availability in controls and methamphetamine abusers evaluated during short or protracted abstinence

Comparison between METH abusers who dropped out of the detoxification program and those that did not

Comparison of striatal DAT availability showed that subjects who dropped out of the detoxification program (most likely relapsed) had significantly lower DAT levels during the short abstinence period than those who completed the detoxification in putamen (1.40 ± 0.3 vs 1.74 ± 0.2; df = 10; p < 0.03) and had a trend for lower values in caudate (1.20 ± 0.2 vs 1.48 ± 0.3; df = 10; p < 0.07). The METH abusers who dropped out performed worse in the neuropsychological tests than those that did not, and these were significant for the pegboard (92 ± 19 vs 67 ± 9; df = 10; p < 0.05) and the delayed recall (8 ± 2 vs 12 ± 3; df = 10; p < 0.05).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Recovery of DAT with protracted METH abstinence

This study documents significant recovery of DAT with protracted abstinence in METH abusers who were able to stay drug free for at least 9 months after the initial evaluation. Moreover, the longer the period between the first and the second evaluation the larger the increases in DAT, suggesting that DAT recovery is in part a function of the length of the abstinence period.

The increases in DAT with protracted abstinence are consistent with recent studies in laboratory animals, which have documented significant recovery from METH-induced DA terminal changes. These studies have shown results that vary from complete recovery to persistent long-lasting changes after METH administration. Complete recovery was reported in a study done in rats, which showed marked reduction in baseline DA levels and in amphetamine-induced increases in DA release 1 week after METH that recovered to normal values 12 months after treatment (Cass and Manning, 1999). Significant, but not complete, recovery in DA function after METH administration was reported by another rodent study that showed marked DA depletions 1 week after METH (30% of controls) that recovered 7 months later (80% of controls) (Friedman et al., 1998). Similarly, imaging studies in nonhuman primates have shown significant recovery of 6-[18F]fluoro-L-dihydroxyphenylalanine and dopamine concentrations at 3-4 months (Melega et al., 1997) and in DAT at 12-15 months after METH treatment (Harvey et al., 2000). In the latter study, the histological analyses of the brains did not reveal evidence of axonal regeneration, as would have been expected if the DAT recovery had been attributable to regeneration of previously damaged terminals (Harvey et al., 2000). However, other studies have reported marked striatal DA reductions in rhesus monkeys even 4 years after METH treatment (Woolverton et al., 1989). These discrepancies are likely to reflect the fact that the extent of recovery may vary across species and age of the animals (Miller et al., 2000) and that it is dependent on the pattern and the amount of METH administered.

Rate of DAT recovery is associated with severity of abuse and days of abstinence

In the METH abusers who were tested twice, the degree of recovery in DAT with protracted abstinence was negatively correlated with the doses and year of METH used, which indicates that severity may ultimately limit the amount and speed of recovery. Similar findings have been reported in laboratory animals for whom the rate of recovery was also shown to be correlated with the doses of METH that were administered to the animals (Bakhit and Gibb, 1981). The fact that the correlation was significant for putamen but did not reach significance for caudate is likely to reflect the low power afforded by the small sample of subjects in whom we were able to obtain follow-up PET scans. The magnitude of the DAT recovery with abstinence was also positively correlated with the time between evaluations. Similar findings are reported in the animal literature in which studies have shown increasingly greater recovery as a function of the days since METH pretreatment (Melega et al., 1997; Friedman et al., 1998).

Comparisons between controls, METH abusers tested during short abstinence, and METH abusers tested during protracted abstinence

Although DAT in METH abusers tested during protracted abstinence did not differ from controls, they were slightly lower. Moreover, failure to achieve a parallel recovery of neuropsychological function with METH abstinence suggests that the lower DAT levels in METH abusers could reflect an incomplete recovery. Similarly, primate studies that reported significant recovery with METH detoxification also described some remaining persistent deficits (Harvey et al., 2000).

Comparisons of DAT between the METH abusers group tested during short abstinence and the group tested during protracted abstinence showed significantly higher DAT in METH abusers tested during protracted abstinence. This again corroborates a significant recovery of DAT with protracted abstinence. The fact that there were no differences in K1 (measure of tracer transport from plasma to brain) between the groups indicates that the changes observed in Bmax/Kd in the METH abusers tested during short but not during protracted abstinence reflect changes in DAT availability and not nonspecific effects of tracer delivery into the brain.

Interpretation of DAT losses with METH and their recovery with protracted abstinence

The losses in DAT induced by METH had been attributed to irreversible neurodegeneration of DA terminals (Ricaurte and McCann, 1992). However, recent studies documenting significant recovery of DAT with abstinence have started to question this interpretation. Also, a postmortem study done in METH abusers that showed reductions in DAT but not in vesicular monoamine transporters (VMAT) interpreted the persistence of VMAT, which is a more stable markers of the DA terminals than DAT (Wilson and Kish, 1996), as an indication of preservation of the DA terminal (Wilson and Kish, 1996). However, inferences from VMAT measures are limited by the fact that VMAT is also expressed in cells other than DA neurons (Schutz et al., 1998).

The DAT recovery with protracted abstinence could reflect either that METH-induced damage to the DA terminals recovers or that the DAT losses reflect adaptive changes (DAT downregulation or internalization). Evidence that METH can decrease protein expression in DA terminals was shown by a study done in rodents that documented METH-induced decreases in mRNA for VMAT and tyrosine hydroxylase (Zhang and Angulo, 1996). METH-induced decreases in DAT could also result from disruption of the process regulating DAT trafficking and internalization (Melikian and Buckley, 1999). Although internalization of DAT by METH has not been documented, it has been shown for amphetamine (Saunders et al., 2000). However, the time course of the DAT recovery (recovery of DAT after METH discontinuation in both laboratory animals and humans takes longer than 6-9 months) is longer than would be expected if the DAT losses were attributable to DAT downregulation or internalization (Iwata et al., 1999; Bachvarov et al., 2001).

An alternative explanation is that the DAT losses reflect DA terminal degeneration and that the DAT increases with protracted abstinence could result from regeneration of the DA nerve terminals or branching of the remaining terminals as an attempt to increase synaptic density in striatum. It is also possible that viable DA terminals overexpress DAT. However, the latter is unlikely because it would result in a decrease in extracellular DA concentration. Although studies have reported DAT upregulation after chronic stimulant administration (cocaine), this was shown shortly after drug discontinuation, and values returned to baseline with detoxification (Malison et al., 1998).

Neuropsychological function did not recover with protracted abstinence

Although DAT recovered significantly with protracted abstinence, neuropsychological function only showed a trend of improvement for some tests. Similarly, the relationship between the changes in DAT with abstinence and the changes in neuropsychological performance did not reach significance. Because we observed previously a correlation between performance on these tests and DAT levels, this suggests that, although there is recovery of DAT levels, there is not a parallel improvement in function. This could occur if the recovery reflects increased arborization of viable terminals that may still be insufficient to compensate for DA terminal loss or if the increases reflect upregulation of DAT in viable terminals. It is also possible that neuropsychological function requires other systems that may have been affected by METH for which recovery may be slower or not present. However, failure to see an association could reflect the poor power afforded by the small sample of subjects who were able to stay drug free. Prospective studies in larger samples of METH abusers are required to assess whether recovery of DAT with protracted abstinence is associated with recovery of neuropsychological function.

Differences between METH abusers who dropped out of the detoxification program and those that did not

At the time of the first evaluation, the METH abusers who were able to stay drug free had higher levels of DAT than the subjects who dropped out of the detoxification program. Thus, it is possible that in part their success to remain drug free was attributable to the fact that, to start with, they had less DA terminal damage than those subjects that were unsuccessful. It is also possible that the degree of DAT recovery is affected by the initial level of impairment and that the recovery in DAT contributed to the ability of the METH abusers to stay drug free. Studies comparing the rate of DAT recovery between METH abusers who are able to stay drug free and those who are not are needed to determine the generalizability of DAT recovery in METH abusers and its prognostic implications.

Summary

The results from this study provide evidence that the DAT losses in METH abusers recover significantly with protracted abstinence. The findings from these studies have implications in the treatment of METH abusers because they suggest that protracted abstinence and proper rehabilitation may reverse some of the METH-induced alterations in brain DA terminals.


    FOOTNOTES

Received Aug. 8, 2001; revised Sept. 13, 2001; accepted Sept. 19, 2001.

This research was performed at Brookhaven National Laboratory and was supported by United States Department of Energy Office of Biological and Environmental Research Grant DE-AC02-98CH10886, National Institute on Drug Abuse Grants DA06891, DA7092-01, and DA00280, General Clinical Research Center (GCRC) at Harbor-University of California, Los Angeles Medical Center National Institutes of Health Grant MO1RR 00425, GCRC at University Hospital Stony Brook National Institutes of Health Grant MO1RR 10710, and the Office of National Drug Control Policy. We thank D. Schlyer and R. Carciello for Cyclotron operations, D. Warner for PET operations, C. Wong for data management, R. Ferrieri, C. Shea, R. MacGregor, V. Garza, and P. King for radiotracer preparation and analysis, and N. Pappas, N. Netusil, and Pauline Carter for patient care.

Correspondence should be addressed to Nora D. Volkow, Medical Department, Brookhaven National Laboratory, Upton, NY 11973. E-mail: volkow{at}bnl.gov.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

  • Bachvarov DR, Houle S, Bachvarova M, Bouthillier J, Adam A, Marceau F (2001) Bradykinin B(2) receptor endocytosis, recycling, and down-regulation assessed using green fluorescent protein conjugates. J Pharmacol Exp Ther 297:19-26[Abstract/Free Full Text].
  • Bakhit C, Gibb JW (1981) Methamphetamine-induced depression of tryptophan hydroxylase: recovery following acute treatment. Eur J Pharmacol 76:229-233[Medline].
  • Bendriem B, Dewey SL, Schlyer DJ, Wolf AP, Volkow ND (1991) Quantitation of the human basal ganglia with positron emission tomography: a phantom study of the effect of contrast and axial positioning. IEEE Trans Med Imaging 10:216-222[Web of Science][Medline].
  • Cass WA, Manning MW (1999) Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine. J Neurosci 19:7653-7660[Abstract/Free Full Text].
  • Friedman SD, Castañeda E, Hodge GK (1998) Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 61:35-44[Medline].
  • Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, Ravert HT, Dannals RF (1993) Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 34:423-431[Web of Science][Medline].
  • Harvey DC, Lacan G, Tanious SP, Melega WP (2000) Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res 871:259-270[Web of Science][Medline].
  • Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, Baldwin RM, Zea-Ponce Y, Zoghbi S, Wang S (1993) Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 90:11965-11969[Abstract/Free Full Text].
  • Iwata K, Ito K, Fukuzaki A, Inaki K, Haga T (1999) Dynamin and rab5 regulate GRK2-dependent internalization of dopamine D2 receptors. Eur J Biochem 263:596-602[Web of Science][Medline].
  • Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer D, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ, Christman DR (1990) Graphical analysis of reversible binding from time activity measurements. J Cereb Blood Flow Metab 10:740-747[Web of Science][Medline].
  • Logan J, Volkow ND, Fowler JS, Wang G-J, Dewey SL, MacGregor R, Schlyer D, Gatley SJ, Pappas N, King P, Hitzemann R, Vitkun S (1994) Effects of blood flow on [11C] raclopride binding in the brain: model simulations and kinetic analysis of PET data. J Cereb Blood Flow Metab 14:995-1010[Web of Science][Medline].
  • Malison RT, Best SE, van Dyck CH, McCance EF, Wallace EA, Laruelle M, Baldwin RM, Seibyl JP, Price LH, Kosten TR, Innis RB (1998) Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I]beta-CIT SPECT. Am J Psychiatry 155:832-834[Abstract/Free Full Text].
  • McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA (1998) Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 18:8417-8422[Abstract/Free Full Text].
  • Melega WP, Raleigh MJ, Stout DB, Lacan G, Huang SC, Phelps ME (1997) Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res 766:113-120[Web of Science][Medline].
  • Melikian HE, Buckley KM (1999) Membrane trafficking regulates the activity of the human dopamine transporter. J Neurosci 19:7699-7710[Abstract/Free Full Text].
  • Miller DB, O'Callaghan JP, Ali SF (2000) Age as a susceptibility factor in the striatal dopaminergic neurotoxicity observed in the mouse following substituted amphetamine exposure. Ann NY Acad Sci 914:194-207[Medline].
  • Ricaurte GA, McCann UD (1992) Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann NY Acad Sci 648:371-382[Web of Science][Medline].
  • Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, Leeb-Lundberg LM, Carvelli L, Javitch JA, Galli A (2000) Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA 97:6850-6855[Abstract/Free Full Text].
  • Schutz B, Schafer MK, Eiden LE, Weihe E (1998) Vesicular amine transporter expression and isoform selection in developing brain, peripheral nervous system and gut. Brain Res Dev Brain Res 106:181-204[Medline].
  • Seiden LS, Sabol KE (1996) Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Res Monogr 163:251-276[Medline].
  • Volkow ND, Ding Y-S, Fowler JS, Wang G-J, Logan J, Gatley SJ, Schlyer DJ, Pappas N (1995) A new PET ligand for the dopamine transporter: Studies in the human brain. J Nucl Med 36:2162-2168[Abstract/Free Full Text].
  • Volkow ND, Ding Y-S, Fowler JS, Wang G-J, Logan J, Gatley SJ, Hitzemann R, Smith G, Fields F, Gur R, Wolf AP (1996) Dopamine transporters decrease with age in healthy subjects. J Nucl Med 37:554-558[Abstract/Free Full Text].
  • Volkow ND, Chang L, Wang G-J, Fowler JS, Leonido-Yee M, Franceschi D, Sedler M, Gatley SJ, Hitzemann R, Ding Y-S, Logan J, Wong C, Miller EN (2001) Dopamine transporter losses in methamphetamine abusers are associated with psychomotor impairment. Am J Psychiatry 158:377-382[Abstract/Free Full Text].
  • Wilson JM, Kish SJ (1996) The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 16:3507-3510[Abstract/Free Full Text].
  • Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699-703[Web of Science][Medline].
  • Woolverton WL, Ricaurte GA, Forno LS, Seiden LS (1989) Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res 486:73-78[Web of Science][Medline].
  • Zhang Y, Angulo JA (1996) Contrasting effects of repeated treatment vs. withdrawal of methamphetamine on tyrosine hydroxylase messenger RNA levels in the ventral tegmental area and substantia nigra zona compacta of the rat brain. Synapse 24:218-223[Web of Science][Medline].

Copyright © 2001 Society for Neuroscience  0270-6474/01/21239414-05$05.00/0


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
M. Schwendt, A. Rocha, R. E. See, A. M. Pacchioni, J. F. McGinty, and P. W. Kalivas
Extended Methamphetamine Self-Administration in Rats Results in a Selective Reduction of Dopamine Transporter Levels in the Prefrontal Cortex and Dorsal Striatum Not Accompanied by Marked Monoaminergic Depletion
J. Pharmacol. Exp. Ther., November 1, 2009; 331(2): 555 - 562.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
I. Boileau, P. Rusjan, S. Houle, D. Wilkins, J. Tong, P. Selby, M. Guttman, J. A. Saint-Cyr, A. A. Wilson, and S. J. Kish
Increased Vesicular Monoamine Transporter Binding during Early Abstinence In Human Methamphetamine Users: Is VMAT2 a Stable Dopamine Neuron Biomarker?
J. Neurosci., September 24, 2008; 28(39): 9850 - 9856.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
K. A. Josephs
Capgras Syndrome and Its Relationship to Neurodegenerative Disease
Arch Neurol, December 1, 2007; 64(12): 1762 - 1766.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
T. Hatzipetros, J. G. Raudensky, J.-J. Soghomonian, and B. K. Yamamoto
Haloperidol Treatment after High-Dose Methamphetamine Administration Is Excitotoxic to GABA Cells in the Substantia Nigra Pars Reticulata
J. Neurosci., May 30, 2007; 27(22): 5895 - 5902.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
A. L. Malizia
The role of emission tomography in pharmacokinetic and pharmacodynamic studies in clinical psychopharmacology
J Psychopharmacol, July 1, 2006; 20(4_suppl): 100 - 107.
[Abstract] [PDF]

Home page
 FASEB J.Home page
W. Jeng, A. Ramkissoon, T. Parman, and P. G. Wells
Prostaglandin H synthase-catalyzed bioactivation of amphetamines to free radical intermediates that cause CNS regional DNA oxidation and nerve terminal degeneration
FASEB J, April 1, 2006; 20(6): 638 - 650.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
Y. Sekine, Y. Ouchi, N. Takei, E. Yoshikawa, K. Nakamura, M. Futatsubashi, H. Okada, Y. Minabe, K. Suzuki, Y. Iwata, et al.
Brain Serotonin Transporter Density and Aggression in Abstinent Methamphetamine Abusers
Arch Gen Psychiatry, January 1, 2006; 63(1): 90 - 100.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
T. L. Jernigan, A. C. Gamst, S. L. Archibald, C. Fennema-Notestine, M. R. Mindt, T. L. Marcotte, R. K. Heaton, R. J. Ellis, and I. Grant
Effects of Methamphetamine Dependence and HIV Infection on Cerebral Morphology
Am J Psychiatry, August 1, 2005; 162(8): 1461 - 1472.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Cherner, S. Letendre, R. K. Heaton, J. Durelle, J. Marquie-Beck, B. Gragg, I. Grant, and the HIV Neurobehavioral Research Center Group
Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine
Neurology, April 26, 2005; 64(8): 1343 - 1347.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
T. E. Nordahl, R. Salo, Y. Natsuaki, G. P. Galloway, C. Waters, C. D. Moore, S. Kile, and M. H. Buonocore
Methamphetamine Users in Sustained Abstinence: A Proton Magnetic Resonance Spectroscopy Study
Arch Gen Psychiatry, April 1, 2005; 62(4): 444 - 452.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
L. Chang, T. Ernst, O. Speck, and C. S. Grob
Additive Effects of HIV and Chronic Methamphetamine Use on Brain Metabolite Abnormalities
Am J Psychiatry, February 1, 2005; 162(2): 361 - 369.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Jayanthi, X. Deng, B. Ladenheim, M. T. McCoy, A. Cluster, N.-s. Cai, and J. L. Cadet
Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis
PNAS, January 18, 2005; 102(3): 868 - 873.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
G.-J. Wang, N. D. Volkow, L. Chang, E. Miller, M. Sedler, R. Hitzemann, W. Zhu, J. Logan, Y. Ma, and J. S. Fowler
Partial Recovery of Brain Metabolism in Methamphetamine Abusers After Protracted Abstinence
Am J Psychiatry, February 1, 2004; 161(2): 242 - 248.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
S. JAYANTHI, X. DENG, P.-A. H. NOAILLES, B. LADENHEIM, and J. L. CADET
Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades
FASEB J, February 1, 2004; 18(2): 238 - 251.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
J. L. CADET, S. JAYANTHI, and X. DENG
Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis
FASEB J, October 1, 2003; 17(13): 1775 - 1788.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
Y. Sekine, Y. Minabe, Y. Ouchi, N. Takei, M. Iyo, K. Nakamura, K. Suzuki, H. Tsukada, H. Okada, E. Yoshikawa, et al.
Association of Dopamine Transporter Loss in the Orbitofrontal and Dorsolateral Prefrontal Cortices With Methamphetamine-Related Psychiatric Symptoms
Am J Psychiatry, September 1, 2003; 160(9): 1699 - 1701.
[Abstract] [Full Text] [PDF]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
T. E. Nordahl, R. Salo, and M. Leamon
Neuropsychological Effects of Chronic Methamphetamine Use on Neurotransmitters and Cognition: A Review
J Neuropsychiatry Clin Neurosci, August 1, 2003; 15(3): 317 - 325.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
N. T. Bello, K. L. Sweigart, J. M. Lakoski, R. Norgren, and A. Hajnal
Restricted feeding with scheduled sucrose access results in an upregulation of the rat dopamine transporter
Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2003; 284(5): R1260 - R1268.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. NewsHome page
J. Rosack
Studies Show How Speed Exacts Toll on Brain
Psychiatr News, January 18, 2002; 37(2): 17 - 17.
[Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (137)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Volkow, N. D.
Right arrow Articles by Logan, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Volkow, N. D.
Right arrow Articles by Logan, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*d-METHAMPHETAMINE
*METHYLPHENIDATE
Medline Plus Health Information
*Methamphetamine

 -
-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help
-
Copyright 2009 by Society for Neuroscience ONLINE ISSN: 1529-2401
-